Genzyme "outperform"

09/27/05 - Robert W. Baird

NEW YORK, September 27 (newratings.com) - Analysts at Robert W Baird maintain their "outperform" rating on Genzyme Corporation (GENZ). The target price is set to $84.

In a research note published this morning, the analysts mention that there is limited understanding of Medicare Part-D among physicians. Physicians seem to favour Fosrenol and Genzyme would need to put in a lot of effort to explain the Medicare Part-D plan to physicians and successfully position Renagel for wider acceptance, the analysts say.